12:00 AM
 | 
Aug 08, 2016
 |  BC Week In Review  |  Clinical News  |  Regulatory

RI-002 regulatory update

FDA issued a complete response letter to a BLA from ADMA for R1-002, an IV immunoglobulin (IVIG), to treat primary...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >